| Bioactivity | SARS-CoV-2-IN-75 (compound 13) is a SARS-CoV-2 inhibitor based on chloroacetamide inhibition. SARS-CoV-2-IN-75 inhibits cellular SARS-CoV-2 replication with an EC68 (half-log reduction in viral titer) of 3 μM[1]. |
| Target | EC68: 3 μM (SARS-CoV-2) |
| Name | SARS-CoV-2-IN-75 |
| CAS | 2738323-08-3 |
| Formula | C23H30ClN3O2 |
| Molar Mass | 415.96 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Ashraf-Uz-Zaman M, et al. Design, Synthesis, X-ray Crystallography, and Biological Activities of Covalent, Non-Peptidic Inhibitors of SARS-CoV-2 Main Protease. ACS Infect Dis. 2024 Jan 8. |
SARS-CoV-2-IN-75
CAS: 2738323-08-3 F: C23H30ClN3O2 W: 415.96
SARS-CoV-2-IN-75 (compound 13) is a SARS-CoV-2 inhibitor based on chloroacetamide inhibition. SARS-CoV-2-IN-75 inhibits
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.